J clin oncol: Pacopani vs amycin for the treatment of advanced soft tissue sarcoma in elderly patients.

Doxorubicin (amycin) is the standard treatment for late-stage non-surgical soft tissue sarcoma (STS).
study aims to determine whether pazopanib has the same efficacy as amycin in treating older STS patients and has better tolerance.
to recruit patients with advanced or metastasis STS who had not been systematically treated in the past, and required ECOG performance status of 0-2 points, with suitable organ function.
800 mg/day) or amycin (75 mg/m2.3 weeks) for continuous treatment for no more than 6 courses.
assess non-poor effectiveness based on progressive survival (PFS).
secondary endpoints were neutral granulocyte reduction and fever neutral granulocytic reduction.
81 patients and 39 patients were treated with paropani or amycin, respectively.
age of the patients was 71 years (60-88 years).
compared to the amycin group, the PFS in the Paropani group was non-shoddy (HR 1.0, 95% CI 0.65-1.53), and the rates of stage 4 neotromycin reduction and fever neotromycin reduction were lower than in the amycin group.
the objective remission rates of 12.3 per cent and 15.4 per cent, respectively, in the Papopani and amycin groups.
the overall survival rate of all patients (HR, 1.08; 95% CI, 0.68 to 1.72; P -0.735).
geriatric assessment showed that 15.8 percent of patients had 2 or more combinations and 28.3 percent had limited daily activity.
as a first-line therapy for 60-year-old STS patients is not inferior to amycin, or can be a first-line treatment option for STS.
.